Home News Releases

News Releases

ImmunoFrontier prepared the CSR of Phase I Study of CHP-NY-ESO-1 in patients with Malignancies Expressing NY-ESO 1 in US.

2013/03/29

ImmunoFrontier completed the CSR of Phase I Study of CHP-NY-ESO-1 in Patients with Refractory Esophageal Cancer Expressing NY-ESO 1 in Japan.

2012/10/17

FDA approved Phase I Study of IMF-001 in US.

2010/09/23

ImmunoFrontier filed an IND application of IMF-001 for Phase I Study in US.

2010/08/13

ImmunoFrontier filed an Application of CHP-NY-ESO-1 for Phase I Study with PMDA to develop for esophageal cancer.

2009/08/17

CHP-NY-ESO-1 project was chosen for NIBIO’s “Practical Application Research Supporting Program for Medicine and Medical Device”.

2009/03/10

1
2